APO Research
Talk to an analyst

APO RESEARCH · REPORT

Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

27 December 2025171 pages

Choose your research edition.

Industry ResearchRecombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Industry Research Report 2026106 pages · $2,950 USDIndustry Growth & TrendsGlobal Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Industry Growth and Trends Forecast to 203279 pages · $3,450 USDMarket StructureGlobal Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032171 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection include Hisun Pharmaceuticals, Shanghai Celgen Biopharma and Sunshine Guojian Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection market size, projected growth trends, production technologies, key applications, and end-use industries.

Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Segment by Company

Hisun Pharmaceuticals

Shanghai Celgen Biopharma

Sunshine Guojian Pharmaceutical

Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Segment by Type

12.5mg per Vial

25mg per Vial

Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Segment by Application

Rheumatoid Arthritis

Ankylosing Spondylitis

Plaque Psoriasis

Other

Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Industry Trends Table 2. Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Industry Drivers Table 3. Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Industry Opportunities and Challenges Table 4. Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Industry Restraints Table 5. Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales Market Share by Manufacturers Table 9. Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Manufacturers, Product Type & Application Table 13. Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of 12.5mg per Vial Table 17. Major Manufacturers of 25mg per Vial Table 18. Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales by Type (2021-2026) & (K Units) Table 20. Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales by Type (2027-2032) & (K Units) Table 21. Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales Market Share by Type (2021-2026) Table 22. Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales Market Share by Type (2027-2032) Table 23. Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Revenue by Type (2021-2026) & (K Units) Table 25. Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Revenue by Type (2027-2032) & (K Units) Table 26. Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Revenue Market Share by Type (2021-2026) Table 27. Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Rheumatoid Arthritis Table 29. Major Manufacturers of Ankylosing Spondylitis Table 30. Major Manufacturers of Plaque Psoriasis Table 31. Major Manufacturers of Other Table 32. Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales by Application (2021-2026) & (K Units) Table 34. Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales by Application (2027-2032) & (K Units) Table 35. Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales Market Share by Application (2021-2026) Table 36. Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales Market Share by Application (2027-2032) Table 37. Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 38. Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Revenue by Application (2021-2026) & (K Units) Table 39. Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Revenue by Application (2027-2032) & (K Units) Table 40. Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Revenue Market Share by Application (2021-2026) Table 41. Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Revenue Market Share by Application (2027-2032) Table 42. Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales by Region (2021-2026) & (K Units) Table 44. Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales Market Share by Region (2021-2026) Table 45. Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales Forecasted by Region (2027-2032) & (K Units) Table 46. Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 48. North America Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales by Country (2021-2026) & (K Units) Table 49. North America Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales by Country (2027-2032) & (K Units) Table 50. Europe Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 51. Europe Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales by Country (2021-2026) & (K Units) Table 52. Europe Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales by Country (2027-2032) & (K Units) Table 53. Asia Pacific Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Asia Pacific Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales by Country (2021-2026) & (K Units) Table 55. Asia Pacific Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales by Country (2027-2032) & (K Units) Table 56. South America, Middle East and Africa Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. South America, Middle East and Africa Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales by Country (2021-2026) & (K Units) Table 58. South America, Middle East and Africa Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales by Country (2027-2032) & (K Units) Table 59. Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Revenue Market Share by Region (2021-2026) Table 63. Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Revenue Market Share by Region (2027-2032) Table 64. Hisun Pharmaceuticals Company Information Table 65. Hisun Pharmaceuticals Business Overview Table 66. Hisun Pharmaceuticals Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Hisun Pharmaceuticals Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Product Portfolio Table 68. Hisun Pharmaceuticals Recent Development Table 69. Shanghai Celgen Biopharma Company Information Table 70. Shanghai Celgen Biopharma Business Overview Table 71. Shanghai Celgen Biopharma Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Shanghai Celgen Biopharma Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Product Portfolio Table 73. Shanghai Celgen Biopharma Recent Development Table 74. Sunshine Guojian Pharmaceutical Company Information Table 75. Sunshine Guojian Pharmaceutical Business Overview Table 76. Sunshine Guojian Pharmaceutical Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Sunshine Guojian Pharmaceutical Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Product Portfolio Table 78. Sunshine Guojian Pharmaceutical Recent Development Table 79. Key Raw Materials Table 80. Raw Materials Key Suppliers Table 81. Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Distributors List Table 82. Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Customers List Table 83. Research Programs/Design for This Report Table 84. Authors List of This Report Table 85. Secondary Sources Table 86. Primary Sources List of Figures Figure 1. Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Product Image Figure 2. Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Market Size (2021-2032) & (US$ Million) Figure 4. Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales (2021-2032) & (K Units) Figure 5. Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. 12.5mg per Vial Image Figure 9. 25mg per Vial Image Figure 10. Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales Market Share by Type (2021-2032) Figure 13. Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Revenue Market Share by Type (2021-2032) Figure 16. Rheumatoid Arthritis Image Figure 17. Ankylosing Spondylitis Image Figure 18. Plaque Psoriasis Image Figure 19. Other Image Figure 20. Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales Market Share by Application (2021-2032) Figure 23. Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Revenue Market Share by Application (2021-2032) Figure 26. North America Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 27. North America Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales Market Share by Country (2021-2032) Figure 28. U.S. Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Canada Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Mexico Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales Market Share by Country (2021-2032) Figure 33. Germany Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 34. France Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 35. U.K. Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Italy Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Netherlands Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales Market Share by Country (2021-2032) Figure 40. China Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Japan Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 42. South Korea Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Southeast Asia Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 44. India Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Australia Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales Market Share by Country (2021-2032) Figure 48. Brazil Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South Africa Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Saudi Arabia Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Turkey Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Argentina Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 53. UAE Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Egypt Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Chile Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Revenue (2021-2032) & (US$ Million) Figure 59. North America Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Revenue (2021-2032) & (US$ Million) Figure 61. Europe Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • 12.5mg per Vial
  • 25mg per Vial
Applications
  • Rheumatoid Arthritis
  • Ankylosing Spondylitis
  • Plaque Psoriasis
  • Other
Companies covered
  • Hisun Pharmaceuticals
  • Shanghai Celgen Biopharma
  • Sunshine Guojian Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Market Dynamics
  1. 2.1 Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Industry Trends
  2. 2.2 Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Industry Drivers
  3. 2.3 Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Industry Opportunities and Challenges
  4. 2.4 Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Industry Restraints
3 Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Market by Manufacturers
  1. 3.1 Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales by Manufacturers (2021-2026)
  3. 3.3 Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Manufacturers, Product Type & Application
  7. 3.7 Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Tier 1, Tier 2, and Tier 3
4 Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Market by Type
  1. 4.1 Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Type Introduction
  2. 4.1.1 12.5mg per Vial
  3. 4.1.2 25mg per Vial
  4. 4.2 Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales by Type
  5. 4.2.1 Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales by Type (2021-2032)
  7. 4.2.3 Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales Market Share by Type (2021-2032)
  8. 4.3 Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Revenue by Type
  9. 4.3.1 Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Revenue by Type (2021-2032)
  11. 4.3.3 Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Revenue Market Share by Type (2021-2032)
5 Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Market by Application
  1. 5.1 Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Application Introduction
  2. 5.1.1 Rheumatoid Arthritis
  3. 5.1.2 Ankylosing Spondylitis
  4. 5.1.3 Plaque Psoriasis
  5. 5.1.4 Other
  6. 5.2 Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales by Application
  7. 5.2.1 Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales by Application (2021-2032)
  9. 5.2.3 Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales Market Share by Application (2021-2032)
  10. 5.3 Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Revenue by Application
  11. 5.3.1 Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Revenue by Application (2021-2032)
  13. 5.3.3 Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Revenue Market Share by Application (2021-2032)
6 Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales by Region
  1. 6.1 Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales by Region (2021-2032)
  3. 6.2.1 Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales by Region (2021-2026)
  4. 6.2.2 Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Revenue by Region
  1. 7.1 Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Revenue by Region
  2. 7.1.1 Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Revenue by Region (2021-2026)
  4. 7.1.3 Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Revenue by Region (2027-2032)
  5. 7.1.4 Global Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Revenue (2021-2032)
  8. 7.2.2 North America Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Revenue (2021-2032)
  11. 7.3.2 Europe Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Hisun Pharmaceuticals
  2. 8.1.1 Hisun Pharmaceuticals Company Information
  3. 8.1.2 Hisun Pharmaceuticals Business Overview
  4. 8.1.3 Hisun Pharmaceuticals Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Hisun Pharmaceuticals Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Product Portfolio
  6. 8.1.5 Hisun Pharmaceuticals Recent Developments
  7. 8.2 Shanghai Celgen Biopharma
  8. 8.2.1 Shanghai Celgen Biopharma Company Information
  9. 8.2.2 Shanghai Celgen Biopharma Business Overview
  10. 8.2.3 Shanghai Celgen Biopharma Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Shanghai Celgen Biopharma Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Product Portfolio
  12. 8.2.5 Shanghai Celgen Biopharma Recent Developments
  13. 8.3 Sunshine Guojian Pharmaceutical
  14. 8.3.1 Sunshine Guojian Pharmaceutical Company Information
  15. 8.3.2 Sunshine Guojian Pharmaceutical Business Overview
  16. 8.3.3 Sunshine Guojian Pharmaceutical Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Sunshine Guojian Pharmaceutical Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Product Portfolio
  18. 8.3.5 Sunshine Guojian Pharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Value Chain Analysis
  2. 9.1.1 Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Production Mode & Process
  6. 9.2 Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Distributors
  9. 9.2.3 Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst